Smell and Taste Symptoms Among Patients With Mild and Moderately Severe COVID-19 Infection in Uganda

Richard Byaruhanga, MMED\textsuperscript{1}, Fiona Kabagenyi, MMED\textsuperscript{2},\textsuperscript{o}, Douglas Ssenyonjo Kagga, MMED\textsuperscript{2}, Christopher Ndoleriire, MMED\textsuperscript{2}, Adriane Kamulegeya, MMED\textsuperscript{3}, Lamech Ssemwogerere, MMED\textsuperscript{4}, Ronald Kiguba, PhD\textsuperscript{5}, Bruce Kirenga, PhD\textsuperscript{6}, and Emily Kakande, MMED\textsuperscript{7}

Abstract

Objective. Patients with coronavirus disease 2019 (COVID-19) may present with smell/taste dysfunctions in addition to the most frequent symptoms (fever, cough, and shortness of breath) or as the first symptom or even the only symptom. There is paucity of documentation of prevalence and characteristics of smell/taste dysfunction in COVID-19 in sub-Saharan Africa. The aim of this study was to determine the prevalence of smell/taste symptoms in our setting to institute local evidence-based practice.

Study Design. Cross-sectional study.

Setting. COVID-19 treatment centers in Uganda.

Methods. Patients hospitalized for COVID-19 at 3 treatment sites from November 2020 to March 2021 were recruited. Following written informed consent, their demographics, comorbidities, and smell/taste symptoms data were collected using a questionnaire.

Results. Of 614 patients recruited, 409 (63.8%) had mild symptoms and 232 (36.2%) had moderate to severe symptoms; 64.3% were male, and the mean age was 48.6 ± 15.51 years. In total, 23.1% were health responders and 12.2% had contact with a positive case. Smell and taste impairment was seen in 425 (66.3%) patients, second to cough (71.6%). Smell and taste impairment was seen in 162 (38.1%) as the first symptom, in 128 (30%) as the only symptom, and significantly more in those with mild COVID-19 symptoms ($P < .001$).

Conclusion. COVID-19 manifests with various symptoms, including impairment of smell and taste. This study shows that smell and taste impairment is common and can be the first and only symptom in less severe COVID-19 infections. Therefore, inclusion in the Ministry of Health guidelines is strongly recommended.

Keywords

COVID-19, smell, taste

Received February 9, 2022; accepted May 9, 2022.

I

nfection with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, is a pandemic that started in early December 2019 in Wuhan, China.\textsuperscript{1} As of December 2021, over 269 million people have been affected globally, with 5.3 million deaths. The hardest hit country in Africa is South Africa, followed by Tunisia. Uganda ranks 12th in Africa and is the second most-hit country after Kenya in East Africa.\textsuperscript{2} The daily update from Uganda Ministry of Health as of December 10, 2021, showed that Uganda had 127,796 cases with 3263 deaths.\textsuperscript{3}

The presentation of COVID-19 varies from mild to severe forms, with the largest number of patients being asymptomatic. As of mid-September 2020, more severe forms were

1Department of Ear Nose and Throat, Uganda Christian University, Mukono, Uganda
2Department of Ear Nose and Throat, Makerere University, Kampala, Uganda
3Department of Oro-maxillofacial Surgery, Makerere University, Kampala, Uganda
4Department of Anaesthesia, Makerere University, Kampala, Uganda
5Department of Pharmacology, Makerere University, Kampala, Uganda
6Lung Institute, Makerere University, Kampala, Uganda
7Department of Ear, Nose and Throat, Mulago National Referral Hospital, Kampala, Uganda

Corresponding Author:
Fiona Kabagenyi, MMED, Department of Ear Nose and Throat, College of Health Sciences, Makerere University, PO Box 7072, Kampala, Uganda.
Email: kabagenyiatwooki6@gmail.com

This Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
seen in patients aged 60 years and older and those with comorbidities such as cardiovascular diseases and diabetes mellitus. The commonest symptoms of COVID-19 that were reported both globally and locally were fever, cough, dyspnea, headache, and myalgias. These symptoms are adequately screened for in the current National Guidelines for Management of COVID-19 from the Ministry of Health of Uganda in addition to history of recent travel out of the country or contact with a COVID-19–positive case. However, atypical symptoms like dysfunction of the senses of smell and taste were reported in several studies as presentations of COVID-19. Unfortunately, patients who had loss of smell and loss of taste were not stipulated as high-risk patients in the Ugandan National Guidelines for COVID-19 triage protocol. These patients would unknowingly be vectors of the disease in the community, as they would otherwise be “asymptomatic.”

Prevalence of loss of smell or taste ranged from 5% to 98%, with a paucity of reports from sub-Saharan Africa. Studies from the Western world and Asia reported that some patients with COVID-19 had loss of smell and taste as the only symptom and others as the first symptom of COVID-19. Most patients in 1 study done in Italy had complete loss of sense of smell and taste, with more than half having it before diagnosis of COVID-19, and 13% had it as their first symptom. Many suggested that a sudden severe new-onset loss of smell or taste should be suspected as COVID-19 until proven otherwise. In fact, a study in France to identify COVID-19 showed the specificity of loss of smell and taste as 90.3% and the positive predictive value as 78.5%. A household study tracing index COVID-19 cases with household members found that loss of smell/taste had the highest positive predictive value (83%) among household contacts. We therefore sought to describe the smell and taste symptoms of patients with COVID-19 in Uganda.

**Methods**

This cross-sectional study was prospectively carried out in 3 largest sites designated by the Ministry of Health (MoH) of Uganda as COVID-19 treatment centers: Mulago National Specialist Hospital and Namboole Treatment Centre in Kampala and Entebbe Regional Referral Hospital in Entebbe. At the time of the study, these centers admitted every person with COVID-19 until proven otherwise.10 In fact, a study in France to identify COVID-19 showed the specificity of loss of smell and taste as 90.3% and the positive predictive value as 78.5%. A household study tracing index COVID-19 cases with household members found that loss of smell/taste had the highest positive predictive value (83%) among household contacts. We therefore sought to describe the smell and taste symptoms of patients with COVID-19 in Uganda.

Statistical Analysis

The questions were coded and the data entered using the EpiData version 3.1 (EpiData Software). The data were exported to Statistical Package for Social Scientists (SPSS) version 23 (SPSS, Inc), where data analysis was done. Participant characteristics were expressed as categorical and/or continuous variables. Continuous variables were expressed as means and standard deviations, while categorical data were expressed as frequencies with their respective proportions. The main outcome of this study was prevalence of smell and taste symptoms, which was presented as frequencies and proportions. We compared the different patient characteristics between the groups that had mild symptoms and those that had moderate to severe symptoms as a secondary objective.

Results

Overall, a total of 614 COVID-19–positive patients were described; 412 (64.3%) were male, and the mean age was 48.6 ± 15.51 years. Specific risks included being a health responder (23.1%) and being in contact with a confirmed case (12.2%). Comorbidities were present in 54% and included hypertension (29.1%), diabetes (20.6%), respiratory disease


do. 05/22), as well as approval from the Ministry of Health (scientific research no. 2020-04-29T15_22_34). Written informed consent was obtained from the patients.

The study was done between November 2020 and March 2021, during the first epidemic peak in Uganda, before different variants (Delta and Omicron) and before any vaccinations were available locally. An interviewer-administered questionnaire (for details, see Supplemental Data S1_crf in the online version of the article) was answered by all documented PCR-tested COVID-19–positive patients admitted on the general wards and high-dependency units (HDUs) who consented to the study. The HDUs had facilities for nasal prong or mask administration of piped oxygen and more health care workers compared to the general wards. If the patient’s condition deteriorated, they would then be stepped up to the intensive care unit (ICU), where intubation and mechanical ventilation facilities were available. In this study, those with mental illness or critically ill requiring intubation and intensive care were excluded. Variables collected in the questionnaire included age, sex, comorbidities, risks factors for COVID-19 (ie, health care responders or close contact with a confirmed COVID-19–positive patient), symptoms (ie, fever, cough, dyspnea, fatigue or muscle pain, diarrhea or nausea). Outcome variables were the specific information about presences of smell/taste symptoms (isolated or combined), including its timing of presentation. The study patients were later grouped as group A (those with mild symptoms, admitted to the general ward) and B (moderate to severe symptoms, admitted to the HDU) for comparison of patient characteristics between the groups. The MoH national guidelines classifies mild cases as asymptomatic cases or those with uncomplicated upper respiratory tract viral infection. Moderate cases present with pneumonia without the need for oxygen, while severe cases require hospital-level interventions such as oxygen therapy.
(2.8%), and sinusitis and allergy (1.1%). The common symptoms that were manifested were cough, followed by smell and taste impairment and then fever. Smell and taste impairment was seen in 425 (66.3%). It was the first symptom in 162 (38.1%) and the only symptom in 128 (30%). Symptom duration was 10.8 ± 11.8 days. Baseline characteristics are shown in Table 1.

With comparison between group A (those with mild symptoms) and group B (those with moderate to severe symptoms) demonstrated in Table 2, significant differences were found with more males being affected, the largest proportions being in those aged above 40 years, and having hypertension. The smell/taste alteration as the first symptom was more in group A at 45.5% compared with group B at 24.7% (P < .001). There was no significant difference with sinusitis/respiratory disease, diabetes, or history of comorbidity.

**Discussion**

Our study shows a high prevalence of smell and taste alteration in COVID-19 patients at 66.3% and mostly in those with mild disease. It was the second most common symptom, with 38% having it as their first symptom and 30% having it as their only symptom. It should be noted that every patient who tested positive was quarantined due to institutional policy at that time.

Tong et al. in their systematic review and meta-analysis, found the prevalence of smell and taste impairment in COVID-19 was 53% and 44%, respectively. Saniasiaya et al. also found a pooled prevalence of 48% of taste disorders in their meta-analysis. Although our prevalence of smell and taste impairment is higher than their global trend, there was no representation from Africa for regional comparison of our study findings. Variations of presentation are noted among geographical regions. Lechien et al. showed a prevalence of 85.6% among 417 COVID-19 patients in a multicenter study done in Europe. In the United States, a prevalence of 73% was reported. In sharp contrast, low prevalence was found in Asia, with frequencies of 30% in Korea, 14.8% in India, 8.9% in Japan, and 5.6% in China. The contrast between Europe and the Americas and Asia was thought to be due to ethnic differences between the number of angiotensin-converting enzyme (ACE) receptors in the olfactory epithelium of whites and Asians. As there is scarce documentation involving the black race, our study presents an opportunity to have data from Africa that may help elucidate differences in racial and ethnic symptoms on presentation.

Qualitative symptoms of smell (phantosmia and parosmia) or taste (phantogeusia and parageusia) have also been shown to be prevalent especially in the wake of long COVID-19. Parosmia was prevalent in 40% of those with previous COVID-19, 6 months after a negative COVID-19 PCR test. Dysgeusia had a pooled prevalence of 41.3%. Regrettably, we did not assess these symptoms in our study, a feature we hope to include in further studies. In addition, objective assessment of the smell and taste dysfunctions yielded higher outcomes than subjective tests. At the time of our study, performing objective chemosensory testing was perceived to increase risk of viral transmission to the investigators, and therefore it was felt prudent to evaluate chemosensory deficits using subjective assessments. However, objective methods will be assessed in future studies to note any differences between these methods. Paderno et al. reported resolution of smell and taste disorders in 87% and 82%, respectively, by 30 days. Risk factors for later resolution included presence of nasal congestion, grade of symptoms, and female sex. We focused more on the magnitude of the smell/taste disorders as a baseline for future studies including recovery rates and interventions to improve quality of life after COVID-19.

Several studies agree with ours concerning smell and taste alterations manifesting more in mild COVID-19. Patients who tested positive for COVID-19 but did not have smell dysfunction were 5 times more likely to be hospitalized, 7 times more likely to be intubated, and 7 times more likely to

| Variable                        | Frequency | Percent |
|---------------------------------|-----------|---------|
| **Sex**                         |           |         |
| Female                          | 229       | 35.7    |
| Male                            | 412       | 64.3    |
| **Specific risk**               |           |         |
| Contact with a confirmed case   | 78        | 12.2    |
| Health responder                | 70        | 23.1    |
| Unknown                         | 493       | 76.9    |
| **Comorbidity**                 |           |         |
| No                              | 295       | 46.0    |
| Yes                             | 346       | 54.0    |
| **Complained about smell/taste**|           |         |
| No                              | 216       | 33.7    |
| Yes                             | 425       | 66.3    |
| **Fever**                       |           |         |
| No                              | 169       | 44.4    |
| Yes                             | 212       | 55.6    |
| **Cough**                       |           |         |
| No                              | 108       | 28.4    |
| Yes                             | 273       | 71.6    |
| **Problems with breathing**     |           |         |
| No                              | 183       | 48.0    |
| Yes                             | 198       | 52.0    |
| **Fatigue**                     |           |         |
| No                              | 265       | 69.5    |
| Yes                             | 116       | 30.5    |
| **Diarrhea**                    |           |         |
| No                              | 353       | 94.0    |
| Yes                             | 23        | 6.0     |
| **Hearing**                     |           |         |
| No                              | 372       | 97.6    |
| Yes                             | 9         | 2.4     |
die than those who had smell dysfunction in 1 meta-analysis. This was proposed for risk stratification. Paderno et al studied 508 patients and found a prevalence of smell disorders in 93.1% in the quarantined patients vs 73.4% in the hospitalized patients. Bianco et al in Italy compared 50 COVID-19–positive patients (hospitalized and nonhospitalized). Nonhospitalized patients had more mild symptoms like altered smell, sore throat, and rhinorrhea while hospitalized patients had more common symptoms like dyspnea, fatigue, fever, and cough. A significant difference was seen between the prevalence of smell alteration in nonhospitalized patients at 81.8% compared with 28.5% in the hospitalized patients. Yan et al reported that hospitalized patients had more mild symptoms like altered smell, sore throat, and rhinorrhea while hospitalized patients had more common symptoms like dyspnea, fatigue, fever, and cough. A significant difference was seen between the prevalence of smell alteration in nonhospitalized patients at 81.8% compared with 28.5% in the hospitalized patients. Yan et al reported that hospitalized patients were 10 times less likely to report smell alterations. Izquierdo-Domínguez et al reported smell and taste dysfunction more in younger (<60 years old) and nonhospitalized patients. Lechien et al also reported a similar trend in those with mild to moderate COVID-19.

Our COVID-19–positive patients had smell and taste loss as their first symptom in 38%. This is higher than most studies. Dell’Era et al noted a 9% prevalence, although 54% generally had loss of smell before being diagnosed. In a multicenter study by Izquierdo-Domínguez et al, 18% to 19% patients reported loss of smell and/or taste as the first symptom of COVID-19. Parderno et al reported 14% had olfactory dysfunction as their first symptom, with 16% reporting gustatory disorders as their first symptom. As regards smell and taste alteration as the only symptom, our study still has higher proportions than Cho et al, who found that 4 of 39 of their COVID-19 patients had smell impairment as their only symptom.

As smell and taste loss has a high positive predictive value of COVID-19, we join several otolaryngology societies in sounding the alarm concerning sudden loss of smell and taste as a symptom for COVID-19. With our study findings, we therefore recommend inclusion of loss of smell and taste as a COVID-19 defining symptom that should be part of triage. As this study was done prospectively, we were able to collect most variables for our study. However, due to the subjective nature of the questionnaire, there may have been recall bias in terms of timing of the smell and taste symptoms. Moreover, for safety concerns, we did not carry out any endoscopic examinations of the nose or any objective smell or taste tests. Using our findings should therefore be done with caution. Our questionnaire also did not inquire about any past problems with smell or taste to rule out any preexisting conditions that could be potential confounders of this study. This would have enriched our study findings. Likewise, we made

### Table 2. Clinical Characteristics Between Group A and Group B.

| Variable                          | Mild symptoms: Group A (n = 409), No. (%) | Moderate to severe symptoms: Group B (n = 232), No. (%) | P value |
|-----------------------------------|------------------------------------------|--------------------------------------------------------|---------|
| Sex                               |                                          |                                                        | .020    |
| Female                            | 160 (39.1)                               | 69 (29.7)                                              |         |
| Male                              | 249 (60.9)                               | 163 (70.3)                                             |         |
| Age, y                            |                                          |                                                        | .006    |
| 0-20                              | 13 (3.2)                                 | 1 (0.4)                                                |         |
| 21-40                             | 137 (33.5)                               | 61 (26.3)                                              |         |
| 41-95                             | 259 (63.3)                               | 170 (73.3)                                             |         |
| Altered smell/taste as first symptom |                                      |                                                        | <.001   |
| No                                | 150 (54.6)                               | 113 (75.3)                                             |         |
| Yes                               | 125 (45.4)                               | 37 (24.7)                                              |         |
| Hypertension                      |                                          |                                                        | <.001   |
| No                                | 302 (73.8)                               | 153 (66.0)                                             |         |
| Yes                               | 107 (26.2)                               | 79 (34.0)                                              |         |
| Sinusitis                         |                                          |                                                        | .053    |
| No                                | 402 (98.3)                               | 232 (100.0)                                            |         |
| Yes                               | 7 (1.7)                                  | 0 (0.0)                                                |         |
| Respiratory disease               |                                          |                                                        | 1.000   |
| No                                | 397 (97.1)                               | 226 (97.4)                                             |         |
| Yes                               | 12 (2.9)                                 | 6 (2.6)                                                |         |
| No history of comorbidity         |                                          |                                                        | .187    |
| No                                | 180 (44.0)                               | 115 (49.6)                                             |         |
| Yes                               | 229 (56.0)                               | 117 (50.4)                                             |         |
| Diabetes                          |                                          |                                                        | .155    |
| No                                | 332 (81.2)                               | 177 (76.3)                                             |         |
| Yes                               | 77 (18.8)                                | 55 (23.7)                                              |         |
no inquiry of qualitative symptoms of smell at inception of the study. This presents an avenue for future studies that would include qualitative symptoms and longer follow-up, especially in the wake of long COVID-19. Although this study prioritized the prevalence of the sensory dysfunctions as a symptom for triage due to its potential contribution to prevent further spread of the COVID-19, a future study evaluating the rates of recovery of sense of smell and taste in our setting would inform local ENT practice to improve quality of life. With the ever-changing trends of the COVID-19 presentation, as witnessed by the recent drop in the prevalence of smell and taste dysfunctions during the Omicron outbreak, it is still important to document the findings in the first wave in case any future patterns resurface.

Conclusion
The proportion of patients with smell/taste symptoms due to COVID-19 during the first wave in our country is high. A significant number presented with smell and taste loss as the first or only symptom. We strongly recommend the listing of smell/taste dysfunction as a high-risk symptom for COVID-19 infection screening. Patients are encouraged to go for PCR testing and isolate according to MoH guidelines, to curb further spread of COVID-19.

Author Contributions
Richard Byaruhanga, conceptualization of the project, drafting of proposal, acquisition of data, supervising the research, data analysis and interpretation, critical revision of proposal and manuscript for intellectual content; Fiona Kabagenyi, conception, drafting and design of proposal, data analysis and interpretation, writing up manuscript; Douglas Ssenyondo Kagga, acquisition of funding, data acquisition, analysis and interpretation, critical review and revision of proposal and manuscript for intellectual content; Christopher Ndoleriire, data analysis and interpretation, critical revision of proposal and manuscript for intellectual content; Adriane Kamulegeya, data analysis and interpretation, critical revision of proposal and manuscript for intellectual content; Lamech Ssemwogerere, data analysis and interpretation, critical revision of proposal and manuscript for intellectual content; Ronald Kiguba, data analysis and interpretation, critical revision of proposal and manuscript for intellectual content; Bruce Kirenga, data acquisition, analysis and interpretation, critical review and revision of proposal and manuscript for intellectual content, approval of final version; Emily Kakande, data analysis and interpretation, critical revision of proposal and manuscript for intellectual content.

Disclosures
Competing interests: None.
Sponsorships: None.
Funding source: Financial support for the research was received through the Makerere RIF project.

ORCID ID
Fiona Kabagenyi https://orcid.org/0000-0002-2287-2809

Supplemental Material
Additional supporting information is available at http://journals.sagepub.com/doi/supp/10.1177/2473974X221108357

References
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33.
2. Coronavirus Update (Live). Accessed December 9, 2021. https://www.worldometers.info/coronavirus/?utm_campaign-homeAdvegas1?
3. COVID-19 report. Accessed December 11, 2021. https://www.health.go.ug/covid/
4. Thevarajan I, Buising KL, Cowie BC. Clinical presentation and management of COVID-19. Med J Aust. 2020;213(3):134-139.
5. Kirenga B, Muttamba W, Kayongo A, et al. Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. BMJ Open Resp Res. 2020;7:e000646.
6. El-Anwar a MW, Elzayat S, Fouad YA. ENT manifestation in COVID-19 patients. Auris Nasus Larynx. 2020;47:559-564.
7. Ministry of Health of Government of Uganda. National Guidelines for COVID-19. 2020. MOH.
8. Mullol J, Abolid I, Mariño-Sánchez F, et al. The loss of smell and taste in the COVID-19 outbreak: a tale of many countries. Curr Allergy Asthma Rep. 2020;20:61.
9. Dell’Era V, Filippo F, Giacomo G, et al. Smell and taste disorders during COVID-19 outbreak: cross-sectional study on 355 patients. Massimiliano Head Neck. 2020;42(7):1591-1596.
10. Cho R, Zion T, Zenon Y, et al. COVID-19 viral load in the severity of and recovery from olfactory and gustatory dysfunction. Laryngoscope. 2020;130(11):2680-2685.
11. Sakallia E, Temirbekova D, Bayria E, et al. Ear nose throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients. Am J Otolaryngol. 2020;41:102622.
12. Lechien JR, Chiesa-Estomba CM, De Siaiti DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251-2261.
13. Izquierdo-Dominguez A, Rojas-Lechuga MJ, Chiesa-Estomba C, et al. Smell and taste dysfunctions in COVID-19 are associated with younger age in ambulatory settings—a multicenter cross-sectional study. J Investig Allergol Clin Immunol. 2020;30(5):346-357.
14. Salmon D, Bartier S, Hautefort C, et al. Self-reported loss of smell without nasal obstruction to identify COVID-19. The multicenter CORANOSMIA cohort study. J Infect. 2020;81(4):614-620.
15. Pellegrino R, Cooper KW, Di Pizio A, et al. Corona viruses and the chemical senses: past, present, and future. Chem Senses. 2020;45:415-422.
16. Tong JY, Wong A, Zhu D, et al. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020;163;3-11.
17. Saniasiaya J, Islam MA, Abdullah B. Prevalence and characteristics of taste disorders in cases of COVID-19: a meta-analysis of 29,349 patients. *Otolaryngol Head Neck Surg.* 2021;165(1):33-42.

18. Kaye R, Chang CWD, Kazahaya K, Brereton J, Denny JC. III. COVID-19 anosmia reporting tool: initial findings. *Otolaryngol Head Neck Surg.* 2020;163(1):132-134.

19. Rabin RC. Lost sense of smell may be a peculiar clue to coronavirus infection. *New York Times*, March 22, 2020. Accessed January 2, 2021. https://www.nytimes.com/2020/03/22/health/coronavirus-symptoms-smell-taste.html

20. Mishra P, Gowda V, Dixit S, Kaushik M. Prevalence of new onset anosmia in COVID-19 patients: is the trend different between European and Indian population? *Indian J Otolaryngol Head Neck Surg.* 2020;72(4):484-487.

21. Komagamine J, Yabuki T. Initial symptoms of patients with coronavirus disease 2019 in Japan. *J Gen Fam Med.* 2021;22(1):61-64.

22. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol.* 2020;77(6):683-690.

23. von Bartheld CS, Hagen MM, Butowt R. Prevalence of chemosensory dysfunction in COVID-19 patients: a systematic review and meta-analysis reveals significant ethnic differences. *medRxiv*. 2020. https://doi.org/10.1101/2020.06.15.20132134

24. Di Stadio A, D’Ascanio L, La Mantia I, Ralli M, Brenner MJ. Parosmia after COVID-19: olfactory training, neuroinflammation and distortions of smell. *Eur Rev Med Pharmacol Sci.* 2022;26(1):1-3.

25. D’Ascanio L, Pandolfini M, Cingolani C, et al. Olfactory dysfunction in COVID-19 patients: prevalence and prognosis for recovering sense of smell. *Otolaryngol Head Neck Surg.* 2021;164(1):82-86.

26. Paderno A, Mattavelli D, Rampinelli V, et al. Olfactory and gustatory outcomes in COVID-19: a prospective evaluation in non-hospitalized subjects. *Otolaryngol Head Neck Surg.* 2020;163(6):1144-1149.

27. Kattar N, Do TM, Unis GD, Migneron MR, Thomas AJ, McCoul ED. Olfactory training for postviral olfactory dysfunction: systematic review and meta-analysis. *Otolaryngol Head Neck Surg.* 2021;164(2):244-254.

28. Goshtasbi K, Pang J, Lehrich BM, et al. Association between olfactory dysfunction and critical illness and mortality in COVID-19: a meta-analysis. *Otolaryngol Head Neck Surg.* 2022;166(2):388-392.

29. Paderno A, Schreiber A, Grammatica A, et al. Smell and taste alterations in Covid19: a cross sectional analysis of different cohorts. *Int Forum Allergy Rhinol.* 2020;10(8):955-962.

30. Bianco MA, Modica DM, Drago GD, et al. Alteration of smell and taste in asymptomatic and symptomatic COVID-19 patients in Sicily, Italy. *Ear Nose Throat J.* 2021;100(2)(suppl):182S-185S.

31. Yan CH, Faraji F, Prajapati DP, Ostrander BT, De Conde AS. Self reported olfactory loss associated with outpatient clinical course in COVID-19. *Int Forum Allergy Rhinol.* 2020;10(7):821-883.